FolateImmune therapy - Endocyte/Purdue University

Drug Profile

FolateImmune therapy - Endocyte/Purdue University

Alternative Names: Folate-conjugated vaccine - Endocyte

Latest Information Update: 17 Dec 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Endocyte; Purdue University
  • Developer Endocyte
  • Class Cancer vaccines; Conjugate-vaccines; Fluoresceins; Haptens; Imaging agents
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Renal cancer

Most Recent Events

  • 17 Dec 2013 Discontinued - Phase-I for Renal cancer in USA (SC)
  • 11 Feb 2009 The phase II trial is discontinued due to a lower than expected rate of accrual but phase I trials continue in renal cell carcinoma
  • 03 Jun 2008 Efficacy and adverse events data from a phase I trial in Renal cancer presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top